Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT00412412
- Locations
- 🇺🇸
Research Site, New York, New York, United States
🇺🇸Research site, Houston, Texas, United States
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: FCR
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 627
- Registration Number
- NCT00391066
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Biological: BIIB019 (Daclizumab High Yield Process)Drug: Placebo
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 621
- Registration Number
- NCT00390221
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Lymphoma, Non-Hodgkin's
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 16
- Registration Number
- NCT00384150
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Lymphoma, Non-Hodgkin's
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 340
- Registration Number
- NCT00363636
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 70
- Registration Number
- NCT00345189
- Locations
- 🇬🇧
Research site, Sutton, Surrey, United Kingdom
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
- Conditions
- B-Cell Chronic Lymphocytic Leukemia
- Interventions
- Drug: CNF2024 (BIIB021)
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2009-06-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 15
- Registration Number
- NCT00344786
- Locations
- 🇺🇸
Research Site, San Diego, California, United States
🇺🇸Research site, Houston, Texas, United States
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 10
- Registration Number
- NCT00319930
Natalizumab Re-Initiation of Dosing
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Biological: BG00002 (natalizumab)
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 404
- Registration Number
- NCT00306592
- Locations
- 🇨🇦
Research Center, New York, Ontario, Canada
🇨🇦Research Site, Montreal, Quebec, Canada
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: IDEC-C2B8 (rituximab)Drug: PlaceboDietary Supplement: Folate
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 54
- Registration Number
- NCT00298272
- Locations
- 🇺🇸
Research Site, Burlington, Vermont, United States
🇺🇸Research site, Chardon, Ohio, United States